JP6538071B2 - 非天然発生のブタ生殖器呼吸器症候群ウイルス（ｐｒｒｓｖ）及び使用する方法 - Google Patents
非天然発生のブタ生殖器呼吸器症候群ウイルス（ｐｒｒｓｖ）及び使用する方法 Download PDFInfo
- Publication number
- JP6538071B2 JP6538071B2 JP2016559325A JP2016559325A JP6538071B2 JP 6538071 B2 JP6538071 B2 JP 6538071B2 JP 2016559325 A JP2016559325 A JP 2016559325A JP 2016559325 A JP2016559325 A JP 2016559325A JP 6538071 B2 JP6538071 B2 JP 6538071B2
- Authority
- JP
- Japan
- Prior art keywords
- prrsv
- nucleic acid
- con
- seq
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 50
- 241000700605 Viruses Species 0.000 title claims description 43
- 210000004392 genitalia Anatomy 0.000 title description 7
- 230000000241 respiratory effect Effects 0.000 title description 7
- 208000011580 syndromic disease Diseases 0.000 title description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 114
- 108020004707 nucleic acids Proteins 0.000 claims description 90
- 102000039446 nucleic acids Human genes 0.000 claims description 90
- 239000000203 mixture Substances 0.000 claims description 31
- 239000002245 particle Substances 0.000 claims description 25
- 239000003937 drug carrier Substances 0.000 claims description 11
- 238000007918 intramuscular administration Methods 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 67
- 108090000765 processed proteins & peptides Proteins 0.000 description 67
- 102000004196 processed proteins & peptides Human genes 0.000 description 66
- 241000282887 Suidae Species 0.000 description 42
- 208000015181 infectious disease Diseases 0.000 description 35
- 241000282898 Sus scrofa Species 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- 125000003275 alpha amino acid group Chemical group 0.000 description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 230000003612 virological effect Effects 0.000 description 19
- 206010058874 Viraemia Diseases 0.000 description 15
- 108020000999 Viral RNA Proteins 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 238000011529 RT qPCR Methods 0.000 description 12
- 235000021052 average daily weight gain Nutrition 0.000 description 12
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 230000003053 immunization Effects 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000009004 PCR Kit Methods 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 108010067674 Viral Nonstructural Proteins Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 235000021051 daily weight gain Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- LTFSLKWFMWZEBD-IMJSIDKUSA-N Ser-Asn Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O LTFSLKWFMWZEBD-IMJSIDKUSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968465P | 2014-03-21 | 2014-03-21 | |
| PCT/IB2015/052214 WO2015140774A1 (en) | 2014-03-21 | 2015-03-25 | A non-naturally occuring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510276A JP2017510276A (ja) | 2017-04-13 |
| JP2017510276A5 JP2017510276A5 (enExample) | 2017-09-14 |
| JP6538071B2 true JP6538071B2 (ja) | 2019-07-03 |
Family
ID=54143830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559325A Active JP6538071B2 (ja) | 2014-03-21 | 2015-03-25 | 非天然発生のブタ生殖器呼吸器症候群ウイルス（ｐｒｒｓｖ）及び使用する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10072046B2 (enExample) |
| EP (1) | EP3119429A4 (enExample) |
| JP (1) | JP6538071B2 (enExample) |
| KR (1) | KR20170002393A (enExample) |
| CN (1) | CN107635579A (enExample) |
| CA (1) | CA2943478A1 (enExample) |
| HK (1) | HK1247128A1 (enExample) |
| MX (1) | MX378873B (enExample) |
| PH (2) | PH12016501854B1 (enExample) |
| RU (1) | RU2687150C2 (enExample) |
| WO (1) | WO2015140774A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015140774A1 (en) | 2014-03-21 | 2015-09-24 | Nutech Ventures | A non-naturally occuring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using |
| TWI652347B (zh) * | 2016-02-18 | 2019-03-01 | 美商益農美國公司 | 豬繁殖與呼吸綜合症疫苗病毒 |
| US20240189418A1 (en) * | 2021-03-31 | 2024-06-13 | The Industry & Academic Cooperation In Chungnam National University (Iac) | Virus vaccine based on virus surface engineering providing increased immunity |
| CN118791578B (zh) * | 2024-07-29 | 2024-12-27 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 猪繁殖与呼吸综合征病毒nsp12蛋白的抗原表位、单克隆抗体及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6380376B1 (en) * | 1992-10-30 | 2002-04-30 | Iowa State University Research Foundation | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
| SK286063B6 (sk) | 1997-05-06 | 2008-02-05 | Boehringer Ingelheim Vetmedica Gmbh | Peptid vyvolávajúci tvorbu protilátok, protilátkareaktívna s týmto peptidom a diagnostická súpravaobsahujúca peptid a protilátku |
| EP2251419B1 (en) | 1999-04-22 | 2012-05-30 | United States Department of Agriculture | Porcine reproductive and respiratory syndrome vaccine, based on isolate JA-142 |
| HUP0204176A3 (en) * | 2000-01-26 | 2003-12-29 | Boehringer Ingelheim Vetmed | Recombinant attenuation of prrsv |
| US20020012670A1 (en) | 2000-01-26 | 2002-01-31 | Knut Elbers | Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV) |
| KR20080064813A (ko) * | 2005-08-30 | 2008-07-09 | 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 | 면역원성이 증강된 ｐｒｒｓｖ 항원을 사용하는 동물의백신화 방법 및 조성물 |
| CN101495138B (zh) * | 2005-11-29 | 2014-01-08 | 衣阿华州立大学研究基金公司 | 猪繁殖与呼吸综合征病毒（prrsv）的保护性抗原决定子的鉴定及其用途 |
| UA108902C2 (uk) * | 2010-11-10 | 2015-06-25 | Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування | |
| US9187731B2 (en) * | 2011-07-29 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus inducing type I interferon in susceptible cells |
| EP2737058A1 (en) * | 2011-07-29 | 2014-06-04 | Boehringer Ingelheim Vetmedica GmbH | INFECTIOUS cDNA CLONE OF EUROPEAN PRRS VIRUS AND USES THEREOF |
| EP2620446A1 (en) * | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| WO2015140774A1 (en) * | 2014-03-21 | 2015-09-24 | Nutech Ventures | A non-naturally occuring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using |
-
2015
- 2015-03-25 WO PCT/IB2015/052214 patent/WO2015140774A1/en not_active Ceased
- 2015-03-25 CA CA2943478A patent/CA2943478A1/en not_active Abandoned
- 2015-03-25 US US15/127,931 patent/US10072046B2/en active Active
- 2015-03-25 EP EP15765669.5A patent/EP3119429A4/en not_active Withdrawn
- 2015-03-25 HK HK18106873.9A patent/HK1247128A1/zh unknown
- 2015-03-25 JP JP2016559325A patent/JP6538071B2/ja active Active
- 2015-03-25 RU RU2016141287A patent/RU2687150C2/ru not_active IP Right Cessation
- 2015-03-25 MX MX2016012276A patent/MX378873B/es unknown
- 2015-03-25 KR KR1020167029357A patent/KR20170002393A/ko not_active Withdrawn
- 2015-03-25 CN CN201580024217.9A patent/CN107635579A/zh active Pending
-
2016
- 2016-09-21 PH PH12016501854A patent/PH12016501854B1/en unknown
-
2018
- 2018-08-03 US US16/054,327 patent/US10738088B2/en active Active
-
2020
- 2020-04-02 PH PH12020550204A patent/PH12020550204A1/en unknown
- 2020-05-28 US US16/886,387 patent/US11136355B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10072046B2 (en) | 2018-09-11 |
| US20200331970A1 (en) | 2020-10-22 |
| HK1247128A1 (zh) | 2018-09-21 |
| PH12020550204A1 (en) | 2021-01-11 |
| KR20170002393A (ko) | 2017-01-06 |
| JP2017510276A (ja) | 2017-04-13 |
| EP3119429A4 (en) | 2018-04-04 |
| CA2943478A1 (en) | 2015-09-24 |
| RU2016141287A3 (enExample) | 2018-06-07 |
| US20190048042A1 (en) | 2019-02-14 |
| US11136355B2 (en) | 2021-10-05 |
| MX2016012276A (es) | 2017-06-12 |
| RU2687150C2 (ru) | 2019-05-07 |
| WO2015140774A1 (en) | 2015-09-24 |
| PH12016501854A1 (en) | 2017-01-09 |
| CN107635579A (zh) | 2018-01-26 |
| MX378873B (es) | 2025-03-11 |
| EP3119429A1 (en) | 2017-01-25 |
| US10738088B2 (en) | 2020-08-11 |
| RU2016141287A (ru) | 2018-04-26 |
| US20170198016A1 (en) | 2017-07-13 |
| PH12016501854B1 (en) | 2017-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2971606T3 (es) | Cepa atenuada del virus de la peste porcina africana desarrollada racionalmente que protege contra la exposición al aislado del virus parental Georgia 2007 | |
| AU2016225119B2 (en) | Porcine Epidemic Diarrhea Virus strains and immunogenic compositions therefrom | |
| JP5893829B2 (ja) | イヌパルボウイルス遺伝子変異株を含むワクチン | |
| KR20220132588A (ko) | 탈최적화된 SARS-CoV-2 및 이의 방법 및 용도 | |
| CN110551695A (zh) | 非洲猪瘟病毒四基因缺失弱毒株及其应用 | |
| KR20170032441A (ko) | 코로나바이러스 | |
| US11136355B2 (en) | Non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) and methods of using | |
| JP2012519471A (ja) | 北米のイヌにおいて広まっているイヌジステンパーウイルスに基づく免疫原性組成物、ワクチンおよび診断法 | |
| CN114107228B (zh) | 缺失十二个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用 | |
| CN112063592A (zh) | 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用 | |
| Tao et al. | Identification and genetic characterization of new bovine viral diarrhea virus genotype 2 strains in pigs isolated in China | |
| CN114015660B (zh) | 缺失十个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用 | |
| WO2020238458A1 (zh) | 用于表达e2蛋白的细胞株及其应用，e2蛋白及其应用 | |
| CN112057611B (zh) | 非洲猪瘟病毒e120r蛋白作为免疫抑制剂的应用及免疫抑制位点敲除毒株的构建 | |
| JP2022507053A (ja) | 新規ブタロタウイルス | |
| CN117778334A (zh) | 表达猪瘟病毒e2蛋白的重组猪伪狂犬病毒株及其制备方法和应用 | |
| CN101257917A (zh) | 针对黄病毒科病毒感染的嵌合多肽及其治疗应用 | |
| Lai Xuan Vu et al. | NON-NATURALLY OCCURRING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) AND METHODS OF USING | |
| CN115927416B (zh) | 嵌合猪瘟病毒、猪瘟标记疫苗及其制备方法和应用 | |
| Xuan Vu et al. | NON-NATURALLY OCCURRING PORCINE REPRODUCTION AND RESPIRATORY SYNDROME VIRUS (PRRSV) AND METHODS OF USING | |
| JP2022521463A (ja) | 新規魚トティウイルス | |
| CN113308440B (zh) | 一种n7-甲基转移酶缺陷型冠状病毒减毒疫苗株及其制备方法与应用 | |
| Sepotokele | Production of plant-expressed virus-like particle vaccines against infectious bronchitis coronavirus and vaccine efficacy in chickens | |
| JP2022520756A (ja) | 新規魚コロナウイルス | |
| Ohe et al. | Search of the Infections Source of feline calicivirus in a Multicat Household |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20170125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170801 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190411 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190605 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6538071 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |